Pertuzumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Pertuzumab
- Pertuzumab: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer
Pertuzumab: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer
One-Sentence Summary
Pertuzumab is an anti-HER2 monoclonal antibody originally developed and approved for HER2-positive breast cancer, typically given in combination with trastuzumab and a taxane. The TxGNN model predicts it may also be effective for progesterone-receptor (PR) positive breast cancer, with 10 clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HER2-positive breast cancer (established indication used with trastuzumab; no Finland licence currently on file) |
| Predicted New Indication | Progesterone-receptor positive breast cancer |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L1 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, pertuzumab is an anti-HER2 monoclonal antibody that inhibits HER2/HER3 heterodimerization, used together with trastuzumab as standard therapy for HER2-positive breast cancer.
Progesterone-receptor status frequently co-occurs with HER2 positivity — the HER2+/hormone-receptor-positive (HR+) subtype is a well-recognized clinical entity representing roughly half of all HER2-overexpressing breast cancers. The predicted "new" indication is therefore best understood as a hormone-receptor-defined stratum of pertuzumab's existing approved population, not a wholly independent drug–disease association.
This is why the evidence base is unusually strong for a "predicted" indication: multiple completed Phase 3 trials (e.g. IMpassion050, the Asia-Pacific pertuzumab neoadjuvant trial, and several pertuzumab-biosimilar equivalence trials) already enrolled HER2+/HR-defined populations, and de-escalation studies (WSG-ADAPT, WSG-TP-II, PERTAIN) specifically examine how hormone-receptor status modifies response to dual HER2 blockade — directly supporting the mechanistic plausibility of extending use into the PR-positive stratum.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04629846 | Phase 3 | Completed | 517 | QL1209 (pertuzumab biosimilar) + trastuzumab + docetaxel vs. reference pertuzumab regimen in HER2+/ER-PR- early or locally advanced breast cancer |
| NCT05802225 | Phase 3 | Active, not recruiting | 398 | BCD-178 vs. Perjeta as neoadjuvant therapy for HER2-positive breast cancer, ER/PR-negative population |
| NCT02326974 | Phase 2 | Active, not recruiting | 164 | T-DM1 + pertuzumab preoperative therapy; explores impact of HER2 heterogeneity on treatment response |
| NCT00545688 | Phase 2 | Completed | 417 | 4-arm neoadjuvant study comparing Herceptin/docetaxel/pertuzumab combinations on pathological complete response |
| NCT06131424 | N/A | Completed | 1151 | Retrospective study of HER2-low prevalence, treatment patterns and outcomes in metastatic breast cancer |
| NCT03058939 | Phase 2 | Withdrawn | 0 | Neoadjuvant weekly paclitaxel response-rate study in Nigerian women with breast cancer (withdrawn, no data) |
| NCT02689921 | Phase 2 | Unknown | 7 | Chemotherapy-free neoadjuvant aromatase inhibitor + pertuzumab/trastuzumab in HR+ (ER+/PR+), HER2+ localized breast cancer |
| NCT03726879 | Phase 3 | Completed | 454 | IMpassion050: atezolizumab vs. placebo added to neoadjuvant chemo + trastuzumab + pertuzumab in early HER2+ breast cancer |
| NCT00999804 | Phase 2 | Active, not recruiting | 128 | Lapatinib + trastuzumab ± endocrine therapy, 12 vs. 24 weeks, in HER2-overexpressing breast cancer |
| NCT04675827 | Phase 2 | Terminated | 139 | DECRESCENDO: de-escalation of adjuvant chemotherapy after pCR with neoadjuvant chemo + dual HER2 blockade, HR-negative/node-negative population |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38906970 | 2024 | RCT (biosimilar equivalence) | British Journal of Cancer | QL1209 pertuzumab biosimilar equivalent to reference pertuzumab + trastuzumab + docetaxel in HER2+/ER-PR- breast cancer |
| 37166817 | 2023 | RCT | JAMA Oncology | WSG-TP-II: endocrine therapy + trastuzumab/pertuzumab vs. de-escalated chemotherapy in HR+/HER2+ early breast cancer |
| 27179402 | 2016 | RCT (5-year follow-up) | Lancet Oncology | NeoSphere 5-year PFS/DFS/safety analysis of neoadjuvant pertuzumab + trastuzumab in HER2+ breast cancer |
| 30106636 | 2018 | RCT (Phase II) | Journal of Clinical Oncology | PERTAIN: trastuzumab + aromatase inhibitor ± pertuzumab in HER2+/HR+ metastatic breast cancer |
| 35640077 | 2022 | Guideline/Review (ASCO) | Journal of Clinical Oncology | Updated ASCO guideline for systemic therapy in HER2-positive advanced breast cancer |
| 28945833 | 2017 | Phase II trial | Annals of Oncology | WSG-ADAPT HER2+/HR- final analysis: 12-week dual blockade ± paclitaxel, predictive markers |
| 37609714 | 2023 | Review (trial rationale) | Future Oncology | DECRESCENDO: rationale for de-escalating chemotherapy in HR-negative, HER2-positive, node-negative early breast cancer |
| 33902424 | 2022 | Review | Endocrine, Metabolic & Immune Disorders Drug Targets | Overview of immunotherapy options for breast cancer, including trastuzumab/pertuzumab context |
| 32905036 | 2020 | Review | Cureus | Literature review of therapeutic strategies for HER2-positive metastatic breast cancer |
| 29291541 | 2018 | Case report | International Journal of Surgery Case Reports | HER2-positive mucinous breast carcinoma case, notes on hormone receptor co-expression |
Finland Market Information
Pertuzumab currently has no marketing authorization on file in Finland (market status: not marketed; 0 authorizations recorded).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (anti-HER2 monoclonal antibody; not conventional cytotoxic chemotherapy) |
| Myelosuppression Risk | Low as monotherapy; risk in practice is largely driven by concurrent chemotherapy partners (e.g. docetaxel, paclitaxel) used in combination regimens |
| Emetogenicity Classification | Minimal to low as monotherapy; combination regimens follow the emetogenicity of the concurrent chemotherapy backbone |
| Monitoring Items | Please refer to the package insert warnings and precautions; anti-HER2 antibody therapy generally requires cardiac function (LVEF) monitoring and infusion-reaction observation |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The predicted PR-positive breast cancer indication is supported by an L1 evidence level, including multiple completed Phase 3 trials, but it substantially overlaps with pertuzumab's existing approved HER2-positive use rather than representing a novel drug–disease relationship. The drug is not currently marketed in Finland and no local safety data are available, so guardrails are needed before any local development or off-label use decision.
To proceed, the following is needed:
- Fimea/TFDA package insert data (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism-of-action documentation from DrugBank or product labeling
- Assessment of the regulatory pathway required for Finland market entry, given current "not marketed" status
- Formal drug-drug interaction (DDI) review, since the current query returned no data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.